XBIO

Xenetic Biosciences, Inc. (XBIO) - 10-Q Summary

Business Context and Reporting Period

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immune-oncology technologies, specifically its proprietary Deoxyribonuclease (DNase) program targeting neutrophil extracellular traps (NETs). The company is currently advancing its systemic DNase program as an adjunctive therapy for pancreatic carcinoma and solid tumors. This report covers the quarterly period ended June 30, 2026.

As of July 31, 2026, there were 2,343,181 shares of common stock outstanding. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Revenue Composition: All revenue is derived from royalty payments related to the PolyXen technology sublicense agreement with Takeda Pharmaceutical Co. Ltd.

Cash Flow: Net cash used in operating activities for the six months ended June 30, 2026, was $1,411,866. There were no cash flows from investing or financing activities during this period.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenue increased 12.0% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 24.0% year-to-date, driven by royalties recognized from certain countries under the Takeda agreement.
• Expense Increases: General and Administrative (G&A) expenses increased significantly by 64.2% in Q2 and 31.5% YTD compared to the prior year. This was primarily due to legal expenses associated with a formal strategic review process.
• R&D Reduction: Research and Development expenses decreased by 15.9% in Q2 and 21.0% YTD, attributed to reduced spending on manufacturing development, Israeli exploratory studies, and consulting costs.
• Equity Changes: All outstanding Series B Preferred Stock (1,454,545 shares) was converted into approximately 45,125 shares of common stock during the quarter.
• Net Loss: The net loss for Q2 2026 increased by 35.0% compared to Q2 2025, though the YTD net loss decreased by 12.9% compared to the prior year.

Guidance, Outlook, and Risks

Strategic Review: The Board has initiated a formal strategic review process with outside advisors to maximize shareholder value. Alternatives under consideration include the sale of all or part of the company, a business combination, or a "reverse merger." No definitive agreement has been reached, and there is no assurance a transaction will be consummated.

Liquidity and Going Concern: The company raised $4.0 million in an underwritten offering in October 2025. Management believes existing resources are adequate to fund operations for at least twelve months. However, the company anticipates needing additional capital in the long term and faces uncertainty regarding future financing terms due to volatile biotech capital markets.

Risks and Contingencies:

• Geopolitical Events: Conflicts in Ukraine and the Middle East, along with associated sanctions, pose risks to economic markets and operations.
• Product Development: No drug candidates have received regulatory approval. Success depends on the advancement of the DNase technology.
• Collaboration Dependence: Revenue is heavily reliant on the Takeda sublicense agreement. Other collaborations (Scripps, UVA, Catalent) are ongoing but have not yet generated revenue.
• Listing Compliance: Risk of failure to maintain Nasdaq listing requirements.

Investor Verification Checklist

• Verify the status and timeline of the strategic review process and any potential M&A activity.
• Confirm the sustainability of royalty revenue from Takeda and the terms of the underlying sublicense agreement.
• Assess the cash runway given the $6.5 million cash balance and continued operating losses.
• Review the details of the Series B Preferred Stock conversion and its impact on share count and dilution.
• Monitor progress on the DNase clinical program and upcoming data readouts from Scripps Research and UVA collaborations.
• Check for any updates on Nasdaq compliance status.